Prospect of improved cardiovascular prognosis

Patients suffering from heart failure with preserved ejection fraction (HFpEF) are very often also affected by cardiometabolic comorbidities such as obesity and type 2 diabetes. Although previous randomized trials suggest benefits of semaglutide and tirzepatide in terms of symptom improvement in people with obesity-related HFpEF, their effect on key endpoints has remained largely unclear.